4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family.
The first TSAO derivative that lacks the amino group at the 3'-spiro moiety has been prepared. This molecule retained its HIV-1 specificity (NNRTI characteristic) but did not select for any of the classical NNRTI-specific mutations in the NNRTI binding pocket, including 138-Lys (TSAO resistant strain).
Lobatón
E
E
Instituto de Química Médica (C.S.I.C.), Madrid, Spain.
Velázquez
S
S
San-Félix
A
A
De Clercq
E
E
Balzarini
J
J
Camarasa
M J
MJ
D019380:Anti-HIV Agents / Q000138:chemical synthesis* / Q000494:pharmacology; D003641:Deamination; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000502:physiology; D015498:HIV-2 / Q000187:drug effects / Q000502:physiology; D006801:Humans; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000138:chemical synthesis* / Q000494:pharmacology; D013141:Spiro Compounds / Q000737:chemistry* / Q000494:pharmacology; D013379:Substrate Specificity; D013936:Thymidine / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology; D014529:Uridine / Q000031:analogs & derivatives; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D013141:Spiro Compounds; D054303:HIV Reverse Transcriptase; D013936:Thymidine; C075132:TSAO-T; D014529:Uridine